Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutathione | 12 | 2023 | 193 | 3.610 |
Why?
|
| Acetylcysteine | 6 | 2023 | 73 | 3.350 |
Why?
|
| Glycine | 10 | 2023 | 160 | 3.060 |
Why?
|
| Insulin Resistance | 7 | 2023 | 638 | 1.840 |
Why?
|
| Cysteine | 5 | 2015 | 133 | 1.710 |
Why?
|
| HIV Infections | 11 | 2021 | 1866 | 1.410 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 6 | 2012 | 28 | 1.360 |
Why?
|
| Oxidative Stress | 7 | 2023 | 796 | 1.280 |
Why?
|
| Mitochondria | 8 | 2023 | 677 | 1.210 |
Why?
|
| Dietary Supplements | 8 | 2023 | 472 | 1.160 |
Why?
|
| Inflammation | 5 | 2023 | 1402 | 1.010 |
Why?
|
| Muscle Strength | 2 | 2021 | 75 | 0.890 |
Why?
|
| Healthy Aging | 1 | 2021 | 8 | 0.780 |
Why?
|
| Dyslipidemias | 3 | 2015 | 229 | 0.760 |
Why?
|
| Body Composition | 6 | 2021 | 513 | 0.710 |
Why?
|
| Diet | 4 | 2015 | 1125 | 0.650 |
Why?
|
| Aging | 5 | 2023 | 1174 | 0.630 |
Why?
|
| Diet Therapy | 2 | 2018 | 42 | 0.630 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 222 | 0.610 |
Why?
|
| Lipid Metabolism | 6 | 2013 | 352 | 0.580 |
Why?
|
| Cognition | 1 | 2021 | 735 | 0.520 |
Why?
|
| Lipodystrophy | 3 | 2006 | 34 | 0.510 |
Why?
|
| Anti-HIV Agents | 2 | 2015 | 305 | 0.490 |
Why?
|
| Hypolipidemic Agents | 5 | 2011 | 177 | 0.480 |
Why?
|
| Leptin | 2 | 2015 | 211 | 0.470 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 79 | 0.460 |
Why?
|
| Exercise Therapy | 1 | 2015 | 150 | 0.430 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 230 | 0.410 |
Why?
|
| Energy Metabolism | 4 | 2012 | 764 | 0.410 |
Why?
|
| Fatty Acids | 2 | 2013 | 338 | 0.400 |
Why?
|
| Lipids | 2 | 2012 | 514 | 0.390 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 165 | 0.340 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 130 | 0.340 |
Why?
|
| Oxidation-Reduction | 6 | 2013 | 444 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2010 | 265 | 0.330 |
Why?
|
| Triglycerides | 3 | 2015 | 562 | 0.330 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2015 | 136 | 0.320 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 477 | 0.320 |
Why?
|
| Niacin | 3 | 2015 | 57 | 0.280 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 424 | 0.270 |
Why?
|
| Lipolysis | 4 | 2010 | 82 | 0.260 |
Why?
|
| Metabolic Syndrome | 2 | 2008 | 330 | 0.260 |
Why?
|
| Mice | 8 | 2024 | 17486 | 0.260 |
Why?
|
| Humans | 30 | 2024 | 123182 | 0.260 |
Why?
|
| Age Factors | 4 | 2021 | 2801 | 0.260 |
Why?
|
| Nelson Syndrome | 1 | 2005 | 2 | 0.260 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 75 | 0.250 |
Why?
|
| Cholesterol, LDL | 3 | 2015 | 557 | 0.250 |
Why?
|
| Human Growth Hormone | 3 | 2015 | 74 | 0.240 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 44 | 0.230 |
Why?
|
| Hypertriglyceridemia | 1 | 2005 | 100 | 0.230 |
Why?
|
| Immune Tolerance | 1 | 2024 | 144 | 0.220 |
Why?
|
| Animals | 11 | 2024 | 33713 | 0.220 |
Why?
|
| Dietary Fats | 1 | 2005 | 296 | 0.220 |
Why?
|
| Palmitates | 3 | 2013 | 19 | 0.220 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 290 | 0.210 |
Why?
|
| Aged | 6 | 2023 | 19088 | 0.210 |
Why?
|
| Hyperthyroidism | 1 | 2001 | 26 | 0.190 |
Why?
|
| Glycine Agents | 1 | 2021 | 8 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2010 | 1226 | 0.190 |
Why?
|
| Cholesterol, HDL | 2 | 2015 | 348 | 0.190 |
Why?
|
| Male | 19 | 2021 | 60083 | 0.190 |
Why?
|
| Body Weight | 1 | 2005 | 999 | 0.180 |
Why?
|
| Free Radical Scavengers | 1 | 2021 | 49 | 0.180 |
Why?
|
| Spinal Fractures | 1 | 2001 | 38 | 0.180 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 96 | 0.180 |
Why?
|
| HIV-1 | 3 | 2013 | 465 | 0.180 |
Why?
|
| Endothelium | 1 | 2021 | 71 | 0.180 |
Why?
|
| Gene Products, vpr | 2 | 2013 | 20 | 0.180 |
Why?
|
| Longevity | 1 | 2022 | 138 | 0.180 |
Why?
|
| Obesity | 1 | 2012 | 2227 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2001 | 114 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 169 | 0.170 |
Why?
|
| Lactation | 1 | 2001 | 187 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 463 | 0.170 |
Why?
|
| Fatigue | 1 | 2021 | 217 | 0.170 |
Why?
|
| Perception | 1 | 2021 | 221 | 0.170 |
Why?
|
| Neutropenia | 1 | 2001 | 202 | 0.170 |
Why?
|
| Middle Aged | 11 | 2015 | 26002 | 0.170 |
Why?
|
| Health Promotion | 1 | 2023 | 389 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 4344 | 0.160 |
Why?
|
| Body Temperature Regulation | 1 | 1998 | 30 | 0.160 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 32 | 0.160 |
Why?
|
| Fenofibrate | 2 | 2011 | 58 | 0.160 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 30 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2024 | 987 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2024 | 573 | 0.150 |
Why?
|
| DNA Damage | 1 | 2021 | 506 | 0.150 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 183 | 0.140 |
Why?
|
| Adult | 9 | 2021 | 29065 | 0.140 |
Why?
|
| Blood Glucose | 2 | 2012 | 1114 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1069 | 0.140 |
Why?
|
| Glycerol | 2 | 2010 | 90 | 0.140 |
Why?
|
| Life Style | 3 | 2011 | 403 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1388 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2008 | 1867 | 0.130 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2015 | 12 | 0.120 |
Why?
|
| Fibric Acids | 1 | 2015 | 6 | 0.120 |
Why?
|
| Azetidines | 1 | 2015 | 55 | 0.120 |
Why?
|
| Antioxidants | 2 | 2018 | 337 | 0.120 |
Why?
|
| Pyrazines | 1 | 2015 | 73 | 0.120 |
Why?
|
| Ezetimibe | 1 | 2015 | 95 | 0.120 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2015 | 69 | 0.120 |
Why?
|
| Genomics | 1 | 2022 | 1478 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 174 | 0.110 |
Why?
|
| Cholesterol, VLDL | 1 | 2013 | 14 | 0.110 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 122 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 406 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 666 | 0.100 |
Why?
|
| Isotopes | 1 | 2011 | 27 | 0.100 |
Why?
|
| Quality of Life | 1 | 2021 | 1932 | 0.100 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 23 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1589 | 0.090 |
Why?
|
| Chromatography, Thin Layer | 2 | 2013 | 41 | 0.090 |
Why?
|
| Adiponectin | 1 | 2011 | 109 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2011 | 183 | 0.090 |
Why?
|
| Calorimetry, Indirect | 1 | 2010 | 60 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 55 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2011 | 206 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 116 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 135 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 135 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6376 | 0.080 |
Why?
|
| Female | 10 | 2021 | 65494 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 326 | 0.080 |
Why?
|
| Syndrome | 2 | 2002 | 1115 | 0.080 |
Why?
|
| Glucose | 1 | 2013 | 866 | 0.080 |
Why?
|
| Kinetics | 1 | 2010 | 1313 | 0.080 |
Why?
|
| Carbon Isotopes | 2 | 2006 | 271 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 715 | 0.070 |
Why?
|
| Exercise | 3 | 2011 | 810 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2005 | 3251 | 0.070 |
Why?
|
| Young Adult | 1 | 2021 | 8885 | 0.070 |
Why?
|
| Esterification | 2 | 2006 | 12 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 937 | 0.070 |
Why?
|
| Diet, Fat-Restricted | 1 | 2006 | 42 | 0.070 |
Why?
|
| Skin Pigmentation | 1 | 2005 | 26 | 0.060 |
Why?
|
| Chylomicrons | 1 | 2005 | 8 | 0.060 |
Why?
|
| Adipocytes | 2 | 2006 | 158 | 0.060 |
Why?
|
| Health Behavior | 1 | 2008 | 381 | 0.060 |
Why?
|
| Postprandial Period | 1 | 2005 | 77 | 0.060 |
Why?
|
| Succinic Acid | 1 | 2024 | 14 | 0.060 |
Why?
|
| Succinates | 1 | 2024 | 20 | 0.060 |
Why?
|
| Everolimus | 1 | 2024 | 46 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 313 | 0.060 |
Why?
|
| Fasting | 2 | 2003 | 296 | 0.060 |
Why?
|
| Cicatrix | 1 | 2005 | 125 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 273 | 0.060 |
Why?
|
| Prognosis | 2 | 2004 | 4508 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2006 | 464 | 0.050 |
Why?
|
| Viral Load | 1 | 2005 | 382 | 0.050 |
Why?
|
| Leucine | 1 | 2003 | 309 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 826 | 0.050 |
Why?
|
| Methimazole | 1 | 2001 | 6 | 0.050 |
Why?
|
| Prevalence | 2 | 2008 | 2407 | 0.050 |
Why?
|
| Propylthiouracil | 1 | 2001 | 9 | 0.050 |
Why?
|
| Organ Size | 1 | 2002 | 412 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 75 | 0.050 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2001 | 39 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2001 | 54 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2001 | 247 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 696 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2001 | 107 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2002 | 225 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 665 | 0.040 |
Why?
|
| Neutrophils | 1 | 2001 | 372 | 0.040 |
Why?
|
| Comorbidity | 1 | 2004 | 1498 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 317 | 0.040 |
Why?
|
| Bone Density | 1 | 2001 | 311 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 533 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2018 | 161 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1998 | 671 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 2838 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 1873 | 0.030 |
Why?
|
| Disease Progression | 1 | 2001 | 2024 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2390 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3334 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 1167 | 0.030 |
Why?
|
| Maze Learning | 1 | 1994 | 125 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 56 | 0.030 |
Why?
|
| Electroconvulsive Therapy | 1 | 1994 | 66 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2013 | 53 | 0.030 |
Why?
|
| Mental Recall | 1 | 1994 | 142 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2013 | 91 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 312 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 812 | 0.020 |
Why?
|
| Liver | 2 | 2006 | 1734 | 0.020 |
Why?
|
| Pregnancy | 1 | 2001 | 7146 | 0.020 |
Why?
|
| India | 1 | 2008 | 217 | 0.020 |
Why?
|
| Calorimetry | 1 | 2006 | 57 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 13 | 0.020 |
Why?
|
| Apolipoprotein B-100 | 1 | 2006 | 33 | 0.020 |
Why?
|
| Deuterium | 1 | 2006 | 106 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 374 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 310 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 131 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2001 | 13889 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 1259 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 19118 | 0.010 |
Why?
|
| HIV | 1 | 2004 | 179 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1240 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2003 | 113 | 0.010 |
Why?
|
| Risk Factors | 2 | 2008 | 10021 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1565 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1283 | 0.010 |
Why?
|
| Homeostasis | 1 | 2003 | 682 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 1338 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 12129 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 6211 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 4269 | 0.010 |
Why?
|
| United States | 1 | 2008 | 10632 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1211 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 3632 | 0.000 |
Why?
|